TrialThe Journal of infection2022

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Xinxue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.